Top of this page
Skip navigation, go straight to the content
Our Science
•
Dapirolizumab pegol
Clinical Study Information - Dapirolizumab pegol
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Lay summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Systemic Lupus Erythematosus | A Phase 2b, randomized, double-blind, PBO-controlled, parallel-group, dose-ranging study followed by an observational period that will evaluate the efficacy of Dapirolizumab Pegol (DZP) in inducing disease control and the safety of DZP in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE) who are receiving standard-of-care medications. | Phase 2 |
SL0023 Ongoing |
NCT02804763 2015-004457-40 |